IFNA2 and infection: The clinical limitations of IFN-α therapy in established infection reflect several fundamental barriers, including cumulative toxicity from sustained exposure, reinforcement of immune exhaustion, failure to eradicate the latent reservoir, and viral antagonism of interferon signaling.